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Patellamides are members of the cyanobactin family of ribosomally synthesized
and post-translationally modified cyclic peptide natural products, many of
which, including some patellamides, are biologically active. A detailed
mechanistic understanding of the biosynthetic pathway would enable the
construction of a biotechnological ‘toolkit’ to make novel analogues of
patellamides that are not found in nature. All but two of the protein domains
involved in patellamide biosynthesis have been characterized. The two domains
of unknown function (DUFs) are homologous to each other and are found at the
C-termini of the multi-domain proteins PatA and PatG. The domain sequence is
found in all cyanobactin-biosynthetic pathways characterized to date, implying
a functional role in cyanobactin biosynthesis. Here, the crystal structure of
the PatG DUF domain is reported and its binding interactions with plausible
substrates are investigated.
1. Introduction
Prokaryotic secondary metabolism creates an array of bioactive
molecules, some of which can be exploited for pharmaceutical
development. Cyanobactins, secondary metabolites of cyanobacteria,
are a superfamily of ribosomally synthesized and post-translationally
modified peptides (RiPPs) that are highly variable with a wide range
of bioactivities (Sivonen et al., 2010). Patellamides, eight-residue
cyclic peptides that contain oxazoline, thiazoline and thiazole
heterocycles and d-amino acids (Schmidt et al., 2005), belong to this
superfamily and have attracted considerable interest owing to the
ability of patellamide D to reverse the effects of multidrug resistance
in human leukaemia cells (Williams & Jacobs, 1993; Houssen &
Jaspars, 2010). These natural products are too structurally complex
for cost-effective de novo chemical synthesis, and this prevents the
creation of novel and diverse analogues with desired properties.
Manipulation of the natural product’s biosynthetic pathway can offer
an alternative, more cost-effective, route to such analogues, but does
require a comprehensive understanding of the individual enzymes
involved. Moreover, the use of the isolated enzymes can allow the
introduction of non-natural functionalities.
Patellamides originate from a longer precursor peptide, which is
modified by a series of post-translational modifying (PTM) enzymes
to yield the final cyclic product. Their biosynthesis can be attributed
to a single operon (patA–patG) encoding the precursor peptide
(PatE) and the enzymes required for processing (PatA, PatD and
PatG; Schmidt et al., 2005; Fig. 1). The precursor peptide includes a
core peptide (or multiple core peptides) that becomes the natural
product, as well as conserved recognition sequences and an
N-terminal leader peptide, which are discarded during maturation
but are required to direct post-translational tailoring. It is assumed,
but has not been proven, that all of the chemical tailoring steps are
required for biological activity. All but one of the chemical trans-
formations for the tailoring steps have been assigned to domains
within the processing enzymes (Agarwal et al., 2012; Schmidt et al.,
2005). The first step is the heterocyclization of PatE core peptide
cysteines, serines and threonines by PatD. This is followed by removal
of the N-terminal recognition elements and leader peptide by the
protease domain of PatA. Finally, PatG catalyzes the macrocycliza-
tion of the modified core peptide, simultaneously removing the
C-terminal recognition sequence. Additionally, PatG is responsible
for the oxidation of thiazolines to thiazoles (Fig. 1). Structural and
mechanistic insights have been reported for the protease domain of
PatA (Houssen et al., 2012; Agarwal et al., 2012), the macrocyclization
domain of PatG (Koehnke et al., 2012; Agarwal et al., 2012), the
heterocyclase TruD (Koehnke et al., 2013; a close homologue of PatD
from the trunkamide pathway) and the apparently inactive prenyl
transferase PatF (Bent et al., 2013). Only epimerization (which is
likely to precede thiazoline oxidation) is unassigned to a protein
domain, but it has been suggested that this could be chemically
spontaneous (Milne et al., 2006). Whether the epimerization and
oxidation occur in the linear or the macrocyclic form is unknown. Two
gene products, PatB and PatC, have been reported as non-essential to
synthesis, and their role is unknown (Schmidt et al., 2005).
PatA and PatG both contain C-terminal domains of unknown
function (DUFs) and these domains are homologous (56% identical)
to each other (Fig. 2a). The gene encoding PatG-DUF (amino-acid
residues 914–1191) was amplified from gDNA isolated from
Prochloron sp. that were isolated from Pacific reef samples. The exact
strain could not be determined and the amino-acid sequence of PatG-
DUF (PatG-DUFsp.) differs at three points (E958D, R959Y and
V1037M) from the deposited amino-acid sequence of PatG-DUF
isolated from P. didemni (PatG-DUFdi; accession No. AAY21556.1;
Fig. 2b). It is unclear as to whether these differences arose as a result
of natural variance amongst species or owing to a cloning artefact.
The DUF domain is conserved in all patellamide-like cyanobactin
biosynthetic pathways characterized to date (Supplementary Fig.
S11), suggesting it may play a functional role. To gain some insight
into the DUF domain, we have determined the crystal structure of
PatG-DUFsp. to a resolution of 1.72 A˚, and using isothermal titration
calorimetry (ITC) and nuclear magnetic resonance spectroscopy
(NMR) we have probed its binding to some plausible substrates: the
precursor peptide and intermediates formed during biosynthesis
(Fig. 1).
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Figure 1
Cartoon schematic summarizing patellamide biosynthesis. All of the required biosynthetic machinery is clustered into a single operon. The precursor peptide (PatE) is
processed by PatD, generating thiazoline and oxazoline heterocycles, cleaved at the N-terminus by PatA and cleaved at the C-terminus, macrocyclized and oxidized by PatG
to form highly modified patellamides.
1 Supporting information has been deposited in the IUCr electronic archive
(Reference: SX5117).
2. Methods
2.1. Expression of native and SeMet PatG-DUF
The C-terminal domain of PatG from Prochloron sp. (PatG-
DUFsp.; amino-acid residues 914–1191) was cloned from full-length
patG into the pHISTEV plasmid with an N-terminal His6 tag and a
Tobacco etch virus (TEV) protease site (Liu & Naismith, 2009). The
protein was expressed in Escherichia coli BL21 (DE3) cells grown in
Luria–Bertani (LB) medium supplemented with 50 mg ml1 kana-
mycin. Cultures were grown at 37C and 200 rev min1 until the
OD600 reached 0.6; the cells were then induced by the addition of
isopropyl -d-1-thiogalactopyranoside (IPTG; final concentration
1 mM) and further grown at 18C and 200 rev min1 overnight.
l-Selenomethionine-labelled (SeMet) PatG-DUFsp. was expressed
from E. coli BL21 (DE3) cells grown in minimal medium supple-
mented with glucose-free nutrient mix, 50 mg ml1 kanamycin and
5% glycerol. This medium was inoculated with an overnight culture
grown in LB, which was washed three times in minimal medium.
After 15 min growth at 37C, 60 mg l1 l-selenomethionine was
added. The cultures were returned to 37C and 200 rev min1 and
grown until the OD600 reached 0.6, when 100 mg l
1 lysine, phenyl-
alanine, threonine and 50 mg l1 isoleucine and valine were added.
After incubation for a further 20 min, expression was induced with
IPTG (final concentration 1 mM) and the cells were grown at 18C
for 24 h. For both native and SeMet variants, the cells were harvested
by centrifugation (4000g, 4C, 15 min).
2.2. Purification of native and SeMet PatG-DUF
Cell pellets were resuspended in lysis buffer [20 mM bis-tris pH 6.8,
150 mM NaCl, 20 mM imidazole, 3 mM -mercaptoethanol (BME),
0.1%(v/v) Triton X-100] supplemented with 0.4 mg DNAse per gram
of wet cell pellets and cOmplete EDTA-free protease-inhibitor
tablets (Roche; one tablet per 50 ml resuspension). The cells were
lysed via passage through a cell disruptor at 207 MPa (Constant
Systems) and the cell debris was removed by centrifugation (40 000g,
4C, 20 min). The supernatant was loaded onto a pre-equilibrated
Ni–NTA column at 4C and the column was washed with 80 column
volumes of lysis buffer. The protein was eluted from the column in
elution buffer [20 mM bis-tris pH 6.8, 150 mM NaCl, 250 mM
imidazole, 3 mM BME, 0.1%(v/v) Triton X-100] and fractions
containing protein were pooled and passed over a desalting column
(Desalt 16/10, GE Healthcare) to exchange them into ‘low imidazole’
buffer (20 mM Tris–HCl pH 8.0, 150 mM NaCl, 20 mM imidazole,
3 mM BME, 10% glycerol). TEV protease was added at a mass:mass
ratio of 1 mg of TEV to 10 mg of protein and the sample was incu-
bated for 2 h at 20C to remove the N-terminal His6 tag. The digested
sample was passed over a second Ni–NTA column and the flow-
through was collected and loaded onto a Superdex 75 gel-filtration
column (GE Healthcare) equilibrated in buffer (10 mM HEPES
pH 7.4, 150 mM NaCl, 1 mM TCEP, 10% glycerol). The purity of the
protein was determined by SDS–PAGE and its integrity was deter-
mined by mass spectrometry. Analysis of the mass spectrum of SeMet
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Figure 2
(a) Sequence alignment of PatA-DUFand PatG-DUFsp.. The conserved C-terminal DUFs of PatA and PatG share 56% identity. Residues found to coordinate Zn
2+ in PatG-
DUFsp. are identified by red triangles. (b) Sequence alignment of PatG-DUF cloned from DNA isolated from Prochloron sp. (PatG-DUFsp.) and PatG-DUF isolated from
P. didemni (PatG-DUFdi). Sequence differences are highlighted in green.
PatG-DUFsp. confirmed the successful incorporation of the four
expected SeMet residues. Native and SeMet PatG-DUFsp. were
concentrated to 4.75 mg ml1 for crystallography.
2.3. Mutagenesis
Mutagenesis of PatG-DUFsp. was performed using established
protocols (Liu & Naismith, 2008).
2.4. CD spectroscopy
Near-UV CD spectra were recorded on a Jasco J-810 spectro-
polarimeter with samples in 10 mM HEPES pH 7.4, 150 mM NaCl,
1 mM TCEP, 10% glycerol.
2.5. Crystallography
Crystal screens were set up with the sitting-drop vapour-diffusion
method using a Gryphon robot (Art Robbins). The protein was
screened against sparse-matrix screens composed of a range of
known crystallization conditions at 20 and 4C (Jancarik & Kim,
1991). Diffraction-quality crystals were grown in a condition
consisting of 0.04M potassium phosphate, 16%(w/v) PEG 8000,
20%(v/v) glycerol. Crystals of SeMet PatG-DUFsp. grew using the
same condition as the native protein. A single SeMet PatG-DUFsp.
crystal was cryoprotected in mother liquor and flash-cooled in liquid
nitrogen. A single-wavelength anomalous dispersion (SAD) data set
was collected at the Se K absorption edge at 100 K on beamline I02 at
Diamond Light Source. The structure was solved using AutoSol and
the chains were built into electron density using AutoBuild from the
PHENIX crystallography suite (Adams et al., 2010). Examination of
the identified anomalous scattering atoms revealed the Se atoms of
the four methionine residues as expected, but also an additional atom
at the interface between one monomer and its symmetry mate. The
atom was coordinated by two histidine residues, an aspartic acid and a
glutamic acid. Based on the anomalous scattering and coordination,
we assign this atom as a Zn2+ ion. A map using the phases calculated
from the anomalous scattering atoms and a map after density
modification of these phases are shown in Supplementary Fig. S2. The
structure was manually rebuilt in Coot (Emsley & Cowtan, 2004) and
refined using REFMAC5 (Murshudov et al., 2011). TLS restraints
were generated for refinement using the TLSMD server (Painter &
Merritt, 2006) and the structure was validated using MolProbity
(Chen et al., 2010). The Zn2+ ion refined with a temperature factor
similar to those of the ligating atoms and no additional Fo  Fc
density was observed at the site, supporting our identification of the
atom as a Zn2+ ion. Full structural statistics are given in Table 1.
All sequence alignments were created using Clustal Omega
(Sievers et al., 2014) and presented using ALINE (Bond & Schu¨t-
telkopf, 2009). All structural images were generated using PyMOL
(DeLano, 2002).
2.6. Expression and purification of 15N PatE and PatD
For biochemical characterization an engineered PatE variant was
used denoted PatE0. PatE0 harbours a single core peptide with the
sequence ITACITFC (corresponding to the natural product patella-
mide D) and a C-terminal His6 tag. PatE
0 and 15N-labelled PatE0 were
produced as described previously (Koehnke et al., 2013). The enzyme
PatD was purified in the same way as previously described for its
homologue TruD (Koehnke et al., 2013).
2.7. Heterocyclization of PatE with PatD
15N PatE0 (100 mM) was incubated with PatD (5 mM) in PatE0
gel-filtration buffer (10 mM HEPES pH 7.4, 150 mM NaCl, 1 mM
TCEP) and the product was purified using size-exclusion chromato-
graphy as described previously (Koehnke et al., 2013). The reaction
was monitored using MALDI-TOF MS as described previously
(Koehnke et al., 2013).
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Figure 3
(a) X-ray crystal structure of PatG-DUFsp. represented as a cartoon. The disulfide bond between Cys1136 and Cys1142 is shown as orange sticks and the Zn
2+ ion is shown as
a grey sphere. PatG-DUFsp. amino acids which differ from those in PatG-DUFdi are highlighted in ball-and-stick representation for clarity. (b) X-ray crystal structure of the
PatG-DUFsp. dimer represented as a cartoon. (c) Enlargement of the Zn
2+-coordination site. Glu977, His1087, Asp1088 and His1090 are shown as green sticks and Glu977*,
His1087*, Asp1088* and His1090* are shown as cyan sticks. Difference electron density (Fo  Fc) contoured at 3 with phases calculated from a model which was refined
without Zn2+ present is shown as a blue isomesh.
2.8. ITC and data analysis
ITC experiments were performed using a VP-ITC instrument
(MicroCal) in PatE0 gel-filtration buffer at 20C. Both PatE0 and
PatG-DUFdi were dialyzed into freshly prepared PatE
0 gel-filtration
buffer for 2 d (changing to fresh buffer after the first day) at 4C to
ensure that the buffers for the experiment were matched. A cell
solution of 40 mM PatG-DUFdi and a syringe solution of 600 mM
PatE0 were prepared (using dialysis buffer to dilute the samples) and
degassed at 18C for 15 min. The PatE0 solution was titrated into the
PatG-DUFdi solution as follows: an initial injection of 2 ml followed
by injections of 5 ml at a speed of 0.5 ml min1 with a delay of 4 min
between injections. The syringe was stirred at 307 rev min1 for the
duration of the experiment. The raw data were processed using the
MicroCal Origin software. The baseline was adjusted and the inte-
grations were performed manually.
2.9. NMR binding experiments
NMR experiments were performed at 10C in a Bruker DRX500
spectrometer equipped with a 5 mm TXIz probe. The instrument was
run using the TopSpin software (Bruker). The sample for binding
experiments consisted of 100 mM 15N PatE0 in PatE0 gel-filtration
buffer supplemented with 5% D2O. and a
1H–15N HSQC spectrum
was recorded. Aliquots of 1.6 mM PatG-DUFdi were added to final
concentrations of 50, 100 and 200 mM and HSQCs were recorded
after each addition. The spectra were overlaid using TopSpin to
identify changes (if any) in the spectra subsequent to the addition of
PatG-DUFdi. The
1H–15N HSQC spectra were acquired with Water-
gate water suppression (Piotto et al., 1992) at 1024 128 points and a
digital resolution of 9.8 and 19.0 Hz for the 1H and 15N dimensions,
respectively. The experiment was repeated using the modified 15N
PatE0 containing four heterocycles under the same conditions. This
resulted in a poorer signal-to-noise ratio, and therefore the experi-
ment was repeated using 250 mM modified 15N PatE0 and aliquots of
2 mM PatG-DUFdi were added to final concentrations of 125, 250 and
500 mM.
3. Results
3.1. Crystal structure of PatG-DUF
The gene encoding PatG-DUFsp. (amino-acid residues 914–1191)
was amplified from gDNA isolated from Prochloron sp. Since we
cannot be certain as to whether the variations between PatG-DUFsp.
and PatG-DUFdi reflect natural variation amongst Prochloron
species or have arisen from errors in the original amplification, we
used site-directed mutagenesis to generate PatG-DUF with the
sequence from P. didemni. Both PatG-DUFsp. (Glu958, Arg959 and
Val1037) and PatG-DUFdi (Asp958, Tyr959 and Met1037) were
purified as described in x2 and a near-UV CD spectrum revealed no
significant difference (Supplementary Fig. S3). We concluded that
either sequence was suitable for use in structural characterization.
Crystallography was carried out on PatG-DUFsp. as it had been
purified first and gave crystals. We carried out biophysical studies
with PatG-DUFdi as we felt that these data would be more infor-
mative with a known database match.
The absence of PatG-DUF homologues in the PDB required
the generation of a SeMet PatG-DUFsp. derivative, and the crystal
structure was solved using single-wavelength anomalous dispersion.
The SeMet PatG-DUFsp. crystal belonged to space group P21212 and
contained one monomer in the asymmetric unit. The structure has
a fold comprising seven -helices and 13 -strands. Analysis with
secondary-structure matching at the European Bioinformatics
Institute (http://www.ebi.ac.uk/msd-srv/ssm/) and TopSearch (https://
topsearch.services.came.sbg.ac.at) both suggest that the fold is novel,
with the closest matches being a series of unrelated enterotoxins
giving r.m.s.d. values of between 3 and 4 A˚ over 80 residues
(Krissinel & Henrick, 2004; Wiederstein et al., 2014). The refined
model contains residues 920–1064 and 1077–1184 (the residue
numbers correspond to full-length PatG). The missing residues are at
the N- and C-termini of the model and in a connecting loop between
-helices 5 and 6, and are presumed to be disordered. The model
includes one disulfide bond between Cys1136 and Cys1142 and a
single Zn2+ ion (Fig. 3a). Glu958 and Arg959 are located on the
opposite face from the Zn2+ ion, whilst Val1037 is located on the edge
of a hydrophobic pocket remote from the zinc (Fig. 3a). The changes
in sequence would seem to be unlikely to alter the structure, which is
consistent with the near-UV CD spectra. Since zinc was not delib-
erately added to any of the purification buffers or crystallization
conditions, it is presumed the Zn2+ ion was bound during protein
expression. The Zn2+ ion is coordinated in a tetrahedral arrangement
by residues Glu977, His1087 and His1090. The fourth coordination
site is occupied by residue Asp1088* from a symmetry mate (PatG-
DUFsp.* ), creating a dimer with two Zn
2+-binding sites (Figs. 3b and
3c). Analysis with PISA (http://www.ebi.ac.uk/pdbe/pisa/; Krissinel &
Henrick, 2007) reveals that there are almost no contacts between the
protein residues, and removing the Zn2+ ions in silico reduces the
complex formation significance score to 0.056, indicating that Zn2+ is
crucial in mediating dimer interactions. Since Zn2+ was not added,
its presence in the crystal could suggest that the dimer is present in
solution. However, PatG-DUF (both PatG-DUFsp. and PatG-DUFdi)
eluted from the gel-filtration column with a retention time consistent
with a monomer (Fig. 4), preventing us from a firm assignment of
dimer versus monomer in solution. Interestingly, the residues
involved in Zn2+ binding are not all conserved in PatA-DUF (Fig. 1a).
While the H1087Y substitution might still coordinate Zn2+, the
H1090R substitution would not. Additionally, these residues are not
well conserved in the majority of the PatG-DUF homologues (with
notable exceptions being TruG-DUFand ArtG-DUF) or in any of the
PatA-DUF homologues (Supplementary Fig. S1). Consequently, we
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Table 1
Data-collection and refinement statistics for SeMet PatG-DUFsp..
Anomalous data were collected using a single crystal on beamline I02 at the Diamond
Light Source. Statistics are average values; values for the highest resolution shell are
given in parentheses.
Data collection
Wavelength (A˚) 0.9797
Space group P21212
Unit-cell parameters (A˚, ) a = 64.1, b = 96.2, c = 40.2,
 =  =  = 90.0
Resolution (A˚) 53.17–1.72 (1.77–1.72)
hI/(I)i 12.1 (3.4)
Rmerge (%) 14.5 (89.6)
Completeness (%) 99.9 (100)
Multiplicity 14.0 (11.3)
Anomalous completeness (%) 99.9 (99.9)
Anomalous multiplicity 7.3 (5.7)
Initial map correlation 0.4
Refinement
R factor (%) 17.5 (23.9)
Rfree (%) 20.0 (29.5)
R.m.s.d., bond lengths (A˚) 0.005
R.m.s.d., bond angles () 0.932
No. of non-H atoms
Protein atoms 2109
Solvent atoms 269
Heterogen atoms 1
B factors (A˚2)
All 26.0
Protein 25.1
Ligand (Zn2+) 12.9
Water 32.8
cannot make any claims regarding the biological relevance of a
dimeric assembly for the DUF domain.
The structure of PatG-DUFsp. is novel and therefore provides no
immediate insight into its function within patellamide biosynthesis. In
an attempt to determine whether the C-terminal DUFs are directly
involved in the biosynthesis, binding experiments between PatG-
DUFdi and the precursor peptide PatE
0, and a modified precursor
subsequent to heterocyclization by PatD, were performed using ITC
and NMR.
3.2. Investigating potential binding partners for PatG-DUFdi
Titrating unmodified PatE0 into a solution of PatG-DUFdi repro-
ducibly results in a binding curve (Supplementary Fig. S4). However,
analysis of the data yields unlikely stoichiometries of around ten
molecules of PatG-DUFdi binding to one molecule of PatE
0. Close
inspection of the cell revealed heavy precipitation at the end of the
experiment, suggesting that we were measuring protein aggregation.
Using 15N-labelled PatE0, a 1H–15N HSQC spectrum was recorded
in the absence and presence of 0.5, 1.0 and 2.0 molar equivalents of
PatG-DUFdi (Supplementary Fig. S5a). The spectra of pure
15N PatE0
in the absence (blue) and presence (red) of 2.0 equivalents of PatG-
DUFdi have been overlaid (Fig. 5a), and clearly show an identical
chemical shift pattern, showing that PatG-DUFdi does not bind the
unmodified precursor peptide. The NMR experiments were repeated
using 15N PatE0 that had been processed with PatD, introducing four
heterocycles (two thiazolines and two oxazolines) within the context
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Figure 4
(a) Superdex 75 gel-filtration chromatogram of gel-filtration standards (Bio-Rad).
(b) Superdex 75 gel-filtration chromatogram of PatG-DUF. (c) Standard curve
(elution volume versus log MW). Interpolating from the standard curve, we can
determine that PatG-DUF elutes from the gel-filtration column as a monomer.
Figure 5
(a) Overlaid 1H–15N HSQC NMR spectra of PatE0 before (blue) and after (red) the
addition of 2.0 equivalents of PatG-DUFdi. (b) Overlaid
1H–15N HSQC NMR
spectra of heterocyclized PatE0 before (blue) and after (red) the addition of 2.0
equivalents of PatG-DUFdi.
of the core peptide. As before, the addition of up to 2.0 equivalents of
PatG-DUFdi to the modified PatE
0 resulted in an identical NMR
spectrum (Fig. 5b and Supplementary Fig. S5b), indicating that the
heterocycle-containing peptide does not bind PatG-DUFdi either.
The known disorder of the leader peptide of PatE (Koehnke et al.,
2013) would suggest that blocking of PatG-DUFdi binding by the
leader peptide is unlikely. At present, we are unable to produce
labelled cleaved precursor or macrocycle in sufficient quantities and
purity for NMR experiments.
4. Conclusions
The patellamide proteins PatA and PatG contain C-terminal domains
of unknown function which are 56% identical to each other and are
conserved in related cyanobactin biosynthetic pathways. X-ray crys-
tallography revealed the structure of PatG-DUFsp. to be a novel fold
and, although a dimer is observed in the crystal, the residues involved
in Zn2+ coordination (which is required for dimerization) are not well
conserved in PatA-DUF or in homologues from other pathways.
Consequently, it is difficult to speculate as to the functional impor-
tance of the dimer. We have been unable to detect any binding to
linear substrates (simple peptides or peptides with heterocycles),
indicating that these are unlikely to be substrates or ligands of the
DUFs. The pitfall in using one technique to assess binding was shown
by the reproducible but functionally meaningless ITC binding curves
that we observed. Further study is required with macrocycles before
we can rule out any binding of the DUF domain to patellamide
substrates. It remains possible that the dimerization of the domain
indicates an interaction between the DUFs, potentially leading to
homodimers of PatA/PatG or even heterodimers of PatA and PatG,
which might be important for the activity of these enzymes in vivo.
Further study is required to investigate such hypotheses. If the DUF
domain has no enzymatic role, coupled with the observation that
the protease domains of PatA and PatG are active in isolation, it
is interesting as to why it is conserved throughout cyanobactin
biosynthetic pathways. However, it also suggests that it could be
excluded from in vitro enzyme-based synthesis systems. This simpli-
fies the design and use of a biotechnological ‘toolkit’ for bioactive
cyclic and linear peptides.
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